Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Filings indexed 398 across all filing types
Latest filing 2025-11-14 Major Shareholding Noti…
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-13 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a 424B3 prospectus supplement filed pursuant to Rule 424(b)(3) under the Securities Act, which is a type of prospectus supplement updating information related to a securities offering. It details the resale of shares by selling stockholders, including the number of shares, ownership percentages, and restrictions on conversion and sale. The document is focused on capital raising and resale of securities, specifically common stock and preferred stock conversions. It is not a financial report, earnings release, management discussion, or regulatory filing unrelated to capital markets. The presence of terms like 'prospectus supplement', 'selling stockholders', 'shares offered', and 'registration' clearly indicates this is a Capital/Financing Update filing. The document length (15,000 characters) and detailed content confirm it is the actual filing, not just an announcement or certification. Therefore, the correct classification is Capital/Financing Update (CAP).
2025-11-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-03 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-03 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.